$PTN
PALATIN TECHNOLOGIES INC Stock $ptn

$ptn Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000165495423006575 Filed on May 15, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$1.760M	$1.196M	$216.1K
YoY Change	128.35%	453.3%	143.51%
Cost Of Revenue	$100.0K	$129.2K	$46.91K
YoY Change	14.26%	175.52%	-15.39%
Gross Profit	$1.660M	$1.066M	$169.2K
YoY Change	142.97%	530.32%	408.06%
Gross Profit Margin	94.32%	89.19%	78.29%
Selling, General & Admin	$5.070M	$3.537M	$3.010M
YoY Change	-20.13%	17.54%	-24.95%
% of Gross Profit	305.42%	331.7%	1778.8%
Research & Development	$7.410M	$4.830M	$4.980M
YoY Change	-0.35%	-3.01%	98.45%
% of Gross Profit	446.39%	452.94%	2943.5%
Depreciation & Amortization	$80.00K	$77.88K	$44.09K
YoY Change	88.55%	76.64%	199.73%
% of Gross Profit	4.82%	7.3%	26.06%
Operating Expenses	$12.48M	$8.497M	$8.037M
YoY Change	-9.46%	5.73%	22.23%
Operating Profit	-$10.82M	-$7.301M	-$7.820M
YoY Change	-17.41%	-6.64%	20.57%
Interest Expense	$100.0K	$3.434K	$3.019K
YoY Change	-70.01%	13.75%
% of Operating Profit
Other Income/Expense, Net		$153.3K	$188.8K
YoY Change		-18.79%	-75.04%
Pretax Income	-$10.71M	-$7.148M	-$7.632M
YoY Change	-16.12%	-6.34%	33.19%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$10.71M	-$7.148M	-$7.632M
YoY Change	-16.12%	-6.34%	33.19%
Net Earnings / Revenue	-608.52%	-597.81%	-3531.56%
Basic Earnings Per Share
Diluted Earnings Per Share	-$0.91	-$0.63	-$31.96K
COMMON SHARES
Basic Shares Outstanding	11.52M shares	11.15M shares	231.7M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$11.00M	$19.63M	$37.72M
YoY Change	-63.26%	-47.95%	-45.05%
Cash & Equivalents	$10.98M	$19.63M	$37.72M
Short-Term Investments	$3.000M
Other Short-Term Assets	$1.900M	$2.278M	$2.705M
YoY Change	-1.68%	-15.8%	-2.01%
Inventory	$526.0K	$630.0K	$1.032M
Prepaid Expenses
Receivables	$2.916M	$1.699M	$790.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$16.32M	$24.24M	$42.25M
YoY Change	-52.82%	-42.62%	-46.78%
LONG-TERM ASSETS
Property, Plant & Equipment	$684.9K	$713.6K	$544.6K
YoY Change	27.0%	31.02%	-61.91%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$56.92K	$56.92K	$56.92K
YoY Change	0.0%	0.0%	-0.01%
Total Long-Term Assets	$1.618M	$1.370M	$1.570M
YoY Change	9.71%	-12.77%	5.64%
TOTAL ASSETS
Total Short-Term Assets	$16.32M	$24.24M	$42.25M
Total Long-Term Assets	$1.618M	$1.370M	$1.570M
Total Assets	$17.94M	$25.61M	$43.82M
YoY Change	-50.27%	-41.55%	-45.82%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.304M	$2.786M	$2.403M
YoY Change	36.29%	15.96%	178.09%
Accrued Expenses	$6.511M	$5.536M	$3.175M
YoY Change	-5.3%	74.34%	-42.73%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$100.0K	$105.0K	$99.60K
YoY Change	-0.91%	5.42%
Total Short-Term Liabilities	$15.13M	$11.85M	$11.98M
YoY Change	-6.94%	-1.05%	19.33%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$73.14K	$178.1K
YoY Change	-100.0%	-58.94%
Other Long-Term Liabilities	$2.083M	$3.771M	$2.955M
YoY Change	-27.19%	27.63%	-62.87%
Total Long-Term Liabilities	$2.083M	$3.771M	$2.955M
YoY Change	-27.19%	27.63%	-62.87%
TOTAL LIABILITIES
Total Short-Term Liabilities	$15.13M	$11.85M	$11.98M
Total Long-Term Liabilities	$2.083M	$3.771M	$2.955M
Total Liabilities	$17.81M	$16.02M	$15.73M
YoY Change	-10.09%	1.81%	-12.58%
SHAREHOLDERS EQUITY
Retained Earnings	-$415.5M	-$404.8M	-$375.2M
YoY Change	7.1%	7.89%
Common Stock	$116.6K	$111.5K	$2.318M
YoY Change	25.73%	-95.19%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$134.1K	$9.593M	$28.09M
YoY Change
Total Liabilities & Shareholders Equity	$17.94M	$25.61M	$43.82M
YoY Change	-50.27%	-41.55%	-45.82%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$10.71M	-$7.148M	-$7.632M
YoY Change	-16.12%	-6.34%	33.19%
Depreciation, Depletion And Amortization	$80.00K	$77.88K	$44.09K
YoY Change	88.55%	76.64%	199.73%
Cash From Operating Activities	-$9.610M	-$1.408M	-$9.491M
YoY Change	24.5%	-85.16%	170.84%
INVESTING ACTIVITIES
Capital Expenditures	$50.00K	$116.9K	-$77.40K
YoY Change	-234.73%	-250.99%	1253.15%
Acquisitions
YoY Change
Other Investing Activities	-$2.990M
YoY Change
Cash From Investing Activities	-$3.050M	-$116.9K	-$77.40K
YoY Change	8118.81%	50.99%	1253.15%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.010M	-25.32K	-37.13K
YoY Change	-4237.65%	-31.81%	705.42%
NET CHANGE
Cash From Operating Activities	-9.610M	-1.408M	-9.491M
Cash From Investing Activities	-3.050M	-116.9K	-77.40K
Cash From Financing Activities	1.010M	-25.32K	-37.13K
Net Change In Cash	-11.65M	-1.551M	-9.606M
YoY Change	49.74%	-83.86%	173.3%
FREE CASH FLOW
Cash From Operating Activities	-$9.610M	-$1.408M	-$9.491M
Capital Expenditures	$50.00K	$116.9K	-$77.40K
Free Cash Flow	-$9.660M	-$1.525M	-$9.414M
YoY Change	25.75%	-83.8%	169.07%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-7301263	usd
	dei	Entity Central Index Key EntityCentralIndexKey	0000911216
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2022Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0	usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0	usd
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	9270947	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	11152680	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1107775	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3425323	shares
CY2022Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	4030	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	4030	shares
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-15543
	dei	Entity Registrant Name EntityRegistrantName	PALATIN TECHNOLOGIES, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	95-4078884
	dei	Entity Address Address Line1 EntityAddressAddressLine1	4B Cedar Brook Drive
	dei	Entity Address City Or Town EntityAddressCityOrTown	Cranbury
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	08512
	dei	City Area Code CityAreaCode	609
	dei	Local Phone Number LocalPhoneNumber	495‑2200
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.01 per share
	dei	Trading Symbol TradingSymbol	PTN
	dei	Security Exchange Name SecurityExchangeName	NYSE
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	11523486	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19632330	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	29939154	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1699110	usd
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1780020	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	630033	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	944471	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2277498	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1932454	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	24238971	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	34596099	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	713567	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	539314	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	599442	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	878465	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	56916	usd
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	56916	usd
CY2023Q1	us-gaap	Assets Assets	25608896	usd
CY2022Q2	us-gaap	Assets Assets	36070794	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	2786313	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	3157617	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5536033	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6875216	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	301169	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	371124	usd
CY2023Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	104998	usd
CY2022Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	100921	usd
CY2023Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3122850	usd
CY2022Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	5754986	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	11851363	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	16259864	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	320490	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	529398	usd
CY2023Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	73141	usd
CY2022Q2	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	152407	usd
CY2023Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3771400	usd
CY2022Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2861250	usd
CY2023Q1	us-gaap	Liabilities Liabilities	16016394	usd
CY2022Q2	us-gaap	Liabilities Liabilities	19802919	usd
CY2023Q1	ptn	Escrowed Proceeds EscrowedProceeds	0	usd
CY2022Q2	ptn	Escrowed Proceeds EscrowedProceeds	-15000000	usd
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue	40	usd
CY2022Q2	us-gaap	Preferred Stock Value PreferredStockValue	40	usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11152680	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	9270947	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	111527	usd
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	92709	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	414302055	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	404168822	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-404821120	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-387993696	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	9592502	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	16267875	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	25608896	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	36070794	usd
CY2023Q1	ptn	Product Revenue Net ProductRevenueNet	1195675	usd
CY2022Q1	ptn	Product Revenue Net ProductRevenueNet	216097	usd
	ptn	Product Revenue Net ProductRevenueNet	3091745	usd
	ptn	Product Revenue Net ProductRevenueNet	447719	usd
CY2023Q1	ptn	License And Contract Revenue LicenseAndContractRevenue	0	usd
CY2022Q1	ptn	License And Contract Revenue LicenseAndContractRevenue	0	usd
	ptn	License And Contract Revenue LicenseAndContractRevenue	0	usd
	ptn	License And Contract Revenue LicenseAndContractRevenue	250000	usd
CY2023Q1	us-gaap	Revenues Revenues	1195675	usd
CY2022Q1	us-gaap	Revenues Revenues	216097	usd
	us-gaap	Revenues Revenues	3091745	usd
	us-gaap	Revenues Revenues	697719	usd
CY2023Q1	ptn	Cost Of Products Sold CostOfProductsSold	129235	usd
CY2022Q1	ptn	Cost Of Products Sold CostOfProductsSold	46908	usd
	ptn	Cost Of Products Sold CostOfProductsSold	314438	usd
	ptn	Cost Of Products Sold CostOfProductsSold	130012	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4830327	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4980074	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15224896	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13891235	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3537376	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3009528	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10220518	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10163830	usd
CY2023Q1	ptn	Gainloss On Purchase Commitment GainlossOnPurchaseCommitment	0	usd
CY2022Q1	ptn	Gainloss On Purchase Commitment GainlossOnPurchaseCommitment	0	usd
	ptn	Gainloss On Purchase Commitment GainlossOnPurchaseCommitment	1027322	usd
	ptn	Gainloss On Purchase Commitment GainlossOnPurchaseCommitment	0	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	8496938	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	8036510	usd
	us-gaap	Operating Expenses OperatingExpenses	24732530	usd
	us-gaap	Operating Expenses OperatingExpenses	24185077	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-7820413	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-21640785	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-23487358	usd
CY2023Q1	us-gaap	Investment Income Net InvestmentIncomeNet	234044	usd
CY2022Q1	us-gaap	Investment Income Net InvestmentIncomeNet	1127	usd
	us-gaap	Investment Income Net InvestmentIncomeNet	509006	usd
	us-gaap	Investment Income Net InvestmentIncomeNet	4100	usd
CY2023Q1	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-77266	usd
CY2022Q1	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	190719	usd
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-352121	usd
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	64000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	3434	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	3019	usd
	us-gaap	Interest Expense InterestExpense	18523	usd
	us-gaap	Interest Expense InterestExpense	11423	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	153344	usd
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	188827	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	138362	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	56677	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7147919	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7631586	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-21502423	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-23430681	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-4674999	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-7147919	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-7631586	usd
	us-gaap	Net Income Loss NetIncomeLoss	-16827424	usd
	us-gaap	Net Income Loss NetIncomeLoss	-23430681	usd
CY2023Q1	ptn	Basic And Diluted Net Loss Per Common Share BasicAndDilutedNetLossPerCommonShare	-0.63
CY2022Q1	ptn	Basic And Diluted Net Loss Per Common Share BasicAndDilutedNetLossPerCommonShare	-0.80
	ptn	Basic And Diluted Net Loss Per Common Share BasicAndDilutedNetLossPerCommonShare	-1.59
	ptn	Basic And Diluted Net Loss Per Common Share BasicAndDilutedNetLossPerCommonShare	-2.46
CY2023Q1	ptn	Weighted Average Number Of Common Shares Outstanding Used In Computing Basic And Diluted WeightedAverageNumberOfCommonSharesOutstandingUsedInComputingBasicAndDiluted	11432380	shares
CY2022Q1	ptn	Weighted Average Number Of Common Shares Outstanding Used In Computing Basic And Diluted WeightedAverageNumberOfCommonSharesOutstandingUsedInComputingBasicAndDiluted	9552214	shares
	ptn	Weighted Average Number Of Common Shares Outstanding Used In Computing Basic And Diluted WeightedAverageNumberOfCommonSharesOutstandingUsedInComputingBasicAndDiluted	10613830	shares
	ptn	Weighted Average Number Of Common Shares Outstanding Used In Computing Basic And Diluted WeightedAverageNumberOfCommonSharesOutstandingUsedInComputingBasicAndDiluted	9537768	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	16343586	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	396757	usd
CY2023Q1	ptn	Redemption Of Convertible Series B Series C Preferred Stock RedemptionOfConvertibleSeriesBSeriesCPreferredStock	0	usd
CY2023Q1	ptn	Warrant Exercises Amount WarrantExercisesAmount	78	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-7147919	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	9592502	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	16267875	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1188918	usd
	ptn	Taxes Withheld Related To Restricted Stock Units Amount TaxesWithheldRelatedToRestrictedStockUnitsAmount	-146062	usd
	ptn	Redemption Of Convertible Series B Series C Preferred Stock Amount RedemptionOfConvertibleSeriesBSeriesCPreferredStockAmount	0	usd
	ptn	Sale Of Common Stock And Warrants Net Of Costs Amount SaleOfCommonStockAndWarrantsNetOfCostsAmount	9109117	usd
	ptn	Warrant Exercises Amount WarrantExercisesAmount	78	usd
	ptn	Reverse Stock Split Fractional Shares Amount ReverseStockSplitFractionalSharesAmount	0	usd
	us-gaap	Net Income Loss NetIncomeLoss	-16827424	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	9592502	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	35196307	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	533779	usd
CY2022Q1	ptn	Taxes Withheld Related To Restricted Stock Units Amount TaxesWithheldRelatedToRestrictedStockUnitsAmount	-13041	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-7631586	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	28085459	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	49651372	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1789947	usd
	ptn	Taxes Withheld Related To Restricted Stock Units Amount TaxesWithheldRelatedToRestrictedStockUnitsAmount	-221311	usd
	ptn	Warrant Exercises Amount WarrantExercisesAmount	280000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	16132	usd
	us-gaap	Net Income Loss NetIncomeLoss	-23430681	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	28085459	usd
	us-gaap	Profit Loss ProfitLoss	16827424	usd
	us-gaap	Profit Loss ProfitLoss	23430681	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	207278	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	84244	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	279023	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	268856	usd
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-352121	usd
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	64000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1188918	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1789947	usd
	ptn	Gainloss On Purchase Commitment GainlossOnPurchaseCommitment	1027322	usd
	ptn	Gainloss On Purchase Commitment GainlossOnPurchaseCommitment	0	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-80910	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-790438	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	0	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	0	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	345044	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-354793	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-314438	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-130012	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-407673	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	224258	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1762089	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1339183	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-2621964	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-278863	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-263235	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-1010416	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-1004400	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-18813237	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-22203901	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	381531	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-381531	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-224258	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	146062	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	221311	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	9109117	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	75189	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	32050	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	78	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	280000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	16132	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	8887944	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	42771	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-10306824	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-22385388	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	29939154	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	60104919	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	19632330	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	37719531	usd
	us-gaap	Interest Paid Net InterestPaidNet	18523	usd
	us-gaap	Interest Paid Net InterestPaidNet	11423	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-404821120	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-7147919	usd
	us-gaap	Net Income Loss NetIncomeLoss	-16827424	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19632330	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	11851363	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Use of Estimates</em> – The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2023Q1	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	18930140	usd
CY2022Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	29740565	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Credit Risk</em> – Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, and accounts receivable. Total cash and cash equivalent balances have exceeded balances insured by the Federal Depository Insurance Company. Currently, product revenues and related accounts receivable are generated primarily from one specialty pharmacy.</p>
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2837912	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2630634	usd
	ptn	Accrued Expensespolicytextblock AccruedExpensespolicytextblock	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Accrued Expenses –</em> Third parties perform a significant portion of the Company’s development activities. The Company reviews the activities performed under all contracts each quarter and accrues expenses and the amount of any reimbursement to be received from its collaborators based upon the estimated amount of work completed considering milestones achieved. Estimating the value or stage of completion of certain services requires judgment based on available information. If the Company does not identify services performed for it but not billed by the service-provider, or if it underestimates or overestimates the value of services performed as of a given date, reported expenses will be understated or overstated.</p>
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3425323	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1107775	shares
	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	279700	shares
	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	280500	shares
CY2020Q3	ptn	Contract Termination Agreement Payments ContractTerminationAgreementPayments	12000000	usd
CY2021Q1	ptn	Contract Termination Agreement Payments ContractTerminationAgreementPayments	4300000	usd
	us-gaap	Related Party Transaction Purchases From Related Party RelatedPartyTransactionPurchasesFromRelatedParty	18194000	usd
	us-gaap	Line Of Credit Facility Increase Accrued Interest LineOfCreditFacilityIncreaseAccruedInterest	2300000	usd
CY2020Q3	ptn	Inventory And Prepaid Expenses Estimated Fair Value InventoryAndPrepaidExpensesEstimatedFairValue	5817795	usd
CY2022Q2	us-gaap	Related Party Transaction Purchases From Related Party RelatedPartyTransactionPurchasesFromRelatedParty	1623795	usd
CY2021Q2	us-gaap	Loss On Contract Termination LossOnContractTermination	4407987	usd
CY2021Q2	ptn	Net Loss NetLoss	2784192	usd
	us-gaap	Long Term Purchase Commitment Amount LongTermPurchaseCommitmentAmount	1027322	usd
CY2017Q3	us-gaap	Increase Decrease In Deferred Revenue And Customer Advances And Deposits IncreaseDecreaseInDeferredRevenueAndCustomerAdvancesAndDeposits	4500000	usd
CY2017Q3	us-gaap	Payments For Restructuring PaymentsForRestructuring	5000000	usd
CY2017Q3	ptn	Taxexpenses taxexpenses	500000	usd
CY2017Q3	us-gaap	Payments To Acquire Receivables PaymentsToAcquireReceivables	7500000	usd
CY2017Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues	92500000	usd
CY2023Q1	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	18930140	usd
CY2017Q4	us-gaap	Officers Compensation OfficersCompensation	417500	usd
CY2017Q4	us-gaap	Payments For Restructuring PaymentsForRestructuring	500000	usd
CY2017Q4	ptn	Taxexpenses taxexpenses	82500	usd
CY2017Q4	us-gaap	Payments To Acquire Receivables PaymentsToAcquireReceivables	3000000	usd
CY2017Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues	37500000	usd
CY2023Q1	ptn	Prepaid Clinical Study Costs PrepaidClinicalStudyCosts	118418	usd
CY2022Q2	ptn	Prepaid Clinical Study Costs PrepaidClinicalStudyCosts	310573	usd
CY2023Q1	ptn	Prepaid Insurance Premiums PrepaidInsurancePremiums	483661	usd
CY2022Q2	ptn	Prepaid Insurance Premiums PrepaidInsurancePremiums	132413	usd
CY2023Q1	ptn	Vyleesi Contractual Advances VyleesiContractualAdvances	815750	usd
CY2022Q2	ptn	Vyleesi Contractual Advances VyleesiContractualAdvances	815750	usd
CY2023Q1	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	859669	usd
CY2022Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	673718	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	2277498	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	1932454	usd
CY2022Q2	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	29740565	usd
CY2023Q1	ptn	Clinical Study Costs ClinicalStudyCosts	4398822	usd
CY2022Q2	ptn	Clinical Study Costs ClinicalStudyCosts	3944798	usd
CY2023Q1	ptn	Other Research Related Expenses OtherResearchRelatedExpenses	86034	usd
CY2022Q2	ptn	Other Research Related Expenses OtherResearchRelatedExpenses	35172	usd
CY2023Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	7504	usd
CY2022Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	351257	usd
CY2023Q1	ptn	Personal Cost PersonalCost	0	usd
CY2022Q2	ptn	Personal Cost PersonalCost	1545896	usd
CY2023Q1	ptn	Accrued Selling Expenses AccruedSellingExpenses	901347	usd
CY2022Q2	ptn	Accrued Selling Expenses AccruedSellingExpenses	840703	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	142326	usd
CY2022Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	157390	usd
CY2023Q1	ptn	Tota Acrrued Liabilities TotaAcrruedLiabilities	5536033	usd
CY2022Q2	ptn	Tota Acrrued Liabilities TotaAcrruedLiabilities	6875216	usd
CY2023Q1	us-gaap	Advances On Inventory Purchases AdvancesOnInventoryPurchases	7837100	usd
CY2023Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3122850	usd
CY2023Q1	ptn	Accrued Other Long Term Liabilities AccruedOtherLongTermLiabilities	3771400	usd
CY2022Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	5754986	usd
CY2022Q2	ptn	Accrued Other Long Term Liabilities AccruedOtherLongTermLiabilities	2861250	usd
	us-gaap	Accounts Receivable Purchase AccountsReceivablePurchase	15750000	usd
	us-gaap	Proceeds From Grantors ProceedsFromGrantors	15000000	usd
	ptn	Voting Of Shares Description VotingOfSharesDescription	The holders of Series C Preferred Stock were entitled to 20,000 votes per share
CY2022Q4	ptn	Description Of Securities Purchase DescriptionOfSecuritiesPurchase	1,020,000 shares of the Company’s common stock, (ii) prefunded warrants (the “Pre-Funded Warrants”) to purchase up to 798,182 shares of the Company’s common stock, and (iii) common stock warrants (the “Common Warrants”) to purchase up to 1,818,182 shares of the Company’s common stock. Each share of common stock was offered with one accompanying Common Warrant with a combined offering price of $5.50. Each Pre-Funded Warrant was offered with one accompanying Common Warrant with a combined offering price of $5.4999
CY2022Q4	ptn	Exercise Price Per Share Warrants Outstanding ExercisePricePerShareWarrantsOutstanding	5.83
CY2022Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	0.0001
	ptn	Shares Of Common Stock SharesOfCommonStock	798182	shares
	us-gaap	Costs And Expenses CostsAndExpenses	9109117	usd
CY2023Q1	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	194245	usd
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	576786	usd
CY2022Q1	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	329146	usd
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	1108693	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1163962	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	15.98
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P7Y1M6D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	33160	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.58
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	274440	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	12.00
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	38274	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	18.21
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	884408	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	13.05
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y3M18D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	430873	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	14.85
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y1M6D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	0	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	453535	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	11.34
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y4M24D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	0	usd
CY2022Q2	ptn	Unvested Performance Based Stock Options Granted To Executive Officers And Other Employees UnvestedPerformanceBasedStockOptionsGrantedToExecutiveOfficersAndOtherEmployees	166233	shares
CY2022Q2	ptn	Unvested Performance Based Stock Options Granted UnvestedPerformanceBasedStockOptionsGranted	18921	shares
CY2020Q2	ptn	Unvested Performances Based Restricted Stock Unit UnvestedPerformancesBasedRestrictedStockUnit	87303	usd
CY2021Q2	ptn	Unvested Performances Based Restricted Stock Unit UnvestedPerformancesBasedRestrictedStockUnit	95167	usd
CY2022Q2	ptn	Unvested Performances Based Restricted Stock Unit UnvestedPerformancesBasedRestrictedStockUnit	60566	usd
CY2023Q1	us-gaap	Restricted Stock Expense RestrictedStockExpense	202512	usd
	us-gaap	Restricted Stock Expense RestrictedStockExpense	612132	usd
CY2022Q1	us-gaap	Restricted Stock Expense RestrictedStockExpense	204633	usd
	us-gaap	Restricted Stock Expense RestrictedStockExpense	681254	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	649149	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures	3312	shares
	ptn	Restricted Stock Vested In Period RestrictedStockVestedInPeriod	-84062	shares
	ptn	Fractional Shares FractionalShares	-6	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	561769	shares
CY2021Q2	ptn	Performance Based Restricted Stock PerformanceBasedRestrictedStock	18000	shares
CY2022Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	50.00
CY2023Q1	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	4674999	usd
	ptn	Decription Of Commission DecriptionOfCommission	The Company pays Canaccord 3.0% of the gross proceeds as a commission

Files In Submission

Name	View Source	Status
0001654954-23-006575-index-headers.html	Edgar Link	pending
0001654954-23-006575-index.html	Edgar Link	pending
0001654954-23-006575.txt	Edgar Link	pending
0001654954-23-006575-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
ptn-20230331.xsd	Edgar Link	pending
ptn_10q.htm	Edgar Link	pending
ptn_10qimg16.jpg	Edgar Link	pending
ptn_10qimg17.jpg	Edgar Link	pending
ptn_ex311.htm	Edgar Link	pending
ptn_ex312.htm	Edgar Link	pending
ptn_ex321.htm	Edgar Link	pending
ptn_ex322.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
ptn-20230331_cal.xml	Edgar Link	unprocessable
ptn-20230331_lab.xml	Edgar Link	unprocessable
ptn-20230331_pre.xml	Edgar Link	unprocessable
ptn_10q_htm.xml	Edgar Link	completed
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
ptn-20230331_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PTN
PALATIN TECHNOLOGIES INC Stock $ptn

2023 Q2 Form 10-Q Financial Statement

#000165495423006575 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PTN PALATIN TECHNOLOGIES INC Stock $ptn

2023 Q2 Form 10-Q Financial Statement

#000165495423006575 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PTN
PALATIN TECHNOLOGIES INC Stock $ptn